(19)
(11) EP 3 464 292 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.10.2022 Bulletin 2022/43

(45) Mention of the grant of the patent:
21.09.2022 Bulletin 2022/38

(21) Application number: 17730638.8

(22) Date of filing: 05.06.2017
(51) International Patent Classification (IPC): 
C07D 491/107(2006.01)
A61P 9/00(2006.01)
 A61K 31/4355(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 491/107; A61K 45/06; A61K 31/4525; A61P 9/10
(86) International application number:
PCT/US2017/035867
(87) International publication number:
WO 2017/214002 (14.12.2017 Gazette 2017/50)

(54)

MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO

MODULATOREN DES BETA-3-ADRENERGEN REZEPTORS DIE SICH FÜR DIE BEHANDLUNG ODER PRÄVENTION VON DAMIT IN ZUSAMMENHANG STEHENDEN ERKRANKUNGEN EIGNEN

MODULATEURS DU RÉCEPTEUR ADRÉNERGIQUE-BÊTA-3 UTILES POUR LE TRAITEMENT ET LA PREVENTION DE TROUBLES ASSOCIES A CE DERNIER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 06.06.2016 US 201662346293 P

(43) Date of publication of application:
10.04.2019 Bulletin 2019/15

(73) Proprietor: Arena Pharmaceuticals, Inc.
New York, NY 10017 (US)

(72) Inventors:
  • TRAN, Thuy-Anh
    San Diego California 92130 (US)
  • DO, Quyen-Quyen
    San Diego California 92127 (US)
  • ULLMAN, Brett
    San Diego California 92105 (US)
  • BLACKBURN, Anthony C.
    San Diego, CA 92128 (US)
  • NAGURA, Maiko
    La Jolia, CA 92037 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)


(56) References cited: : 
WO-A1-01/43744
WO-A1-2010/058318
 WO-A1-99/65895
WO-A2-2006/060122
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).